BCRX Biocryst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCRX

Price (delayed)

$4.375

Market cap

$901.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$1.64B

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights
Biocryst Pharmaceuticals's gross profit has increased by 24% YoY and by 4.7% from the previous quarter
BCRX's revenue is up by 22% YoY and by 4.4% QoQ
BCRX's equity has dropped by 55% year-on-year and by 11% since the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 40% QoQ and by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biocryst.com
Peers: RGEN SRPT NNVC NVAX

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
206.15M
Market cap
$901.91M
Enterprise value
$1.64B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.94
Earnings
Revenue
$331.41M
EBIT
-$117.99M
EBITDA
-$116.34M
Free cash flow
-$97.31M
Per share
EPS
-$1.18
Free cash flow per share
-$0.51
Book value per share
-$2.22
Revenue per share
$1.72
TBVPS
$2.69
Balance sheet
Total assets
$516.96M
Total liabilities
$972.49M
Debt
$848.71M
Equity
-$455.53M
Working capital
$345.98M
Liquidity
Debt to equity
-1.86
Current ratio
3.31
Quick ratio
2.99
Net debt/EBITDA
-6.33
Margins
EBITDA margin
-35.1%
Gross margin
98.6%
Net margin
-68.4%
Operating margin
-31.3%
Efficiency
Return on assets
-43.6%
Return on equity
N/A
Return on invested capital
-10.8%
Return on capital employed
-32.2%
Return on sales
-35.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-0.79%
1 week
-5.1%
1 month
-12.67%
1 year
-41.82%
YTD
-26.96%
QTD
-13.88%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$331.41M
Gross profit
$326.75M
Operating income
-$103.71M
Net income
-$226.54M
Gross margin
98.6%
Net margin
-68.4%
The operating margin has grown by 43% YoY and by 7% from the previous quarter
BCRX's operating income is up by 30% YoY and by 3.4% QoQ
BCRX's net margin is up by 25% YoY and by 8% QoQ
Biocryst Pharmaceuticals's gross profit has increased by 24% YoY and by 4.7% from the previous quarter

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.94
BCRX's EPS is up by 11% YoY and by 6% from the previous quarter
BCRX's equity has dropped by 55% year-on-year and by 11% since the previous quarter
The P/S is 87% lower than the 5-year quarterly average of 19.2 and 42% lower than the last 4 quarters average of 4.4
BCRX's revenue is up by 22% YoY and by 4.4% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
The ROIC rose by 39% YoY and by 10% QoQ
BCRX's ROS is up by 34% YoY and by 9% from the previous quarter
The company's return on assets rose by 5% YoY and by 2.7% QoQ

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 47% lower than its total liabilities
Biocryst Pharmaceuticals's quick ratio has decreased by 40% QoQ and by 34% YoY
Biocryst Pharmaceuticals's current ratio has decreased by 40% from the previous quarter and by 32% YoY
BCRX's equity has dropped by 55% year-on-year and by 11% since the previous quarter
BCRX's debt to equity is up by 26% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.